
Core Insights - Analysts project that PTC Therapeutics (PTCT) will report a quarterly loss of $1 per share, marking a 62.4% increase in losses year over year, with revenues expected to decline by 10.1% to $192.12 million [1] - The consensus EPS estimate has been revised upward by 2% in the past 30 days, indicating a reassessment of earnings projections by covering analysts [2] - Changes in earnings projections are crucial for predicting investor reactions, as empirical studies show a strong correlation between earnings estimate trends and short-term stock price movements [3] Revenue Estimates - Analysts estimate that 'Revenues- Net product revenue' will be $134.09 million, reflecting a decrease of 23.2% from the same quarter last year [5] - The consensus for 'Revenues- Royalty revenue' is projected at $57.75 million, indicating an increase of 56.7% year over year [5] - 'Revenues- Net product revenue- Emflaza' is expected to reach $47.55 million, showing a decline of 28% from the prior-year quarter [5] - 'Revenues- Net product revenue- Translarna' is anticipated to be $83.86 million, representing a decrease of 12.6% year over year [6] Stock Performance - Over the past month, PTC Therapeutics shares have experienced a return of -2.3%, compared to a -6.7% change in the Zacks S&P 500 composite [6] - Based on its Zacks Rank 3 (Hold), PTCT is expected to perform in line with the overall market in the near future [6]